Using videomicroscopy to predict bleeding risk in patients with bleeding disorders

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the use of sublingual videomicroscopy to analyze capillary density as a non-invasive method for predicting bleeding risk in patients with von Willebrand disease and Glanzmann thrombasthenia. By assessing the sublingual capillary bed, researchers hope to identify patients at higher risk of bleeding due to angiodysplasias. The study involves adult patients with significant forms of these conditions and includes blood sample collection for further analysis.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patient with a significant form of von Willebrand disease (according to the inclusion criteria of the Willebrand Disease French Reference Center), a Glanzmann Thrombasthenia, a moderate to severe Haemophilia A or a woman carrying the hemophilia gene
* Social insured patient

Exclusion Criteria:

* Minor patient
* Refusal of consent
* Person benefiting from a system of legal protection
* Pregnant patient

Where it's running

• CHU de Lille
  Lille, Nord, France Recruiting

Study contacts

• Principal investigator: Antoine Rauch, MD,PhD — University Hospital, Lille
• Study coordinator: Antoine Rauch, MD,PhD
• Email: antoine.rauch@chru-lille.fr
• Phone: 3 20445962 (poste 29673)

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ATHNdataset registry for people with bleeding and clotting disorders

  This registry collects health, treatment, and patient-reported information from people with bleeding and clotting disorders seen at ATHN-affiliated centers to help improve care and outcomes.

  Recruiting American Thrombosis and Hemostasis Network · Hickory, North Carolina · NCT06820515

• Eptacog beta to treat and prevent serious bleeding in Glanzmann thrombasthenia

  This will test whether eptacog beta can stop acute bleeds and help prevent serious bleeding in people with Glanzmann thrombasthenia who have a severe bleeding history.

  Recruiting Phase 2 Emory University · Atlanta, Georgia · NCT07136857

• Prophylactic treatment for heavy menstrual bleeding in women with von Willebrand disease

  This study tests if a new treatment can help women with von Willebrand disease who have heavy menstrual bleeding feel better during their periods.

  Recruiting at 2 sites Phase 3 Unity Health Toronto · Kingston, Ontario and 1 other locations · NCT06205095

• Progestin options for heavy periods in young people with inherited bleeding disorders

  This project will test two progestin menstrual treatments—a levonorgestrel IUD and daily norethindrone acetate—in adolescents and young adults (ages 10–24) with inherited bleeding disorders to see which better reduces heavy menstrual bleeding over six months.

  Recruiting at 6 sites Oregon Health and Science University · Palo Alto, California and 7 other locations · NCT05916469

• Evaluating VGA039 in Healthy Volunteers and Patients with Von Willebrand Disease

  This study is testing a new treatment called VGA039 to see if it is safe and effective for healthy people and those with von Willebrand Disease.

  Recruiting at 24 sites Phase 1/2 Vega Therapeutics, Inc · Los Angeles, California and 24 other locations · NCT05776069

• Understanding cardiovascular and thromboembolic events in patients with von Willebrand disease in the French West

  This study looks at how often blood clots and heart rhythm problems happen in adults with von Willebrand disease in the French West to better understand their risks.

  Recruiting University Hospital, Brest · Angers and 5 other locations · NCT05773638

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.